U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C32H39NO4
Molecular Weight 501.6564
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FEXOFENADINE

SMILES

CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN2CCC(CC2)C(O)(C3=CC=CC=C3)C4=CC=CC=C4

InChI

InChIKey=RWTNPBWLLIMQHL-UHFFFAOYSA-N
InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)

HIDE SMILES / InChI
Molecular Formula C32H39NO4
Molecular Weight 501.6564
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including https://www.drugbank.ca/drugs/DB00950

Fexofenadine is a second-generation, long lasting H1-receptor antagonist (antihistamine) which has a selective and peripheral H1-antagonist action. Histamine is a chemical that causes many of the signs that are part of allergic reactions, such as the swelling of tissues. Histamine is released from histamine-storing cells (mast cells) and attaches to other cells that have receptors for histamine. The attachment of the histamine to the receptors causes the cell to be "activated," releasing other chemicals which produce the effects that we associate with allergy. Fexofenadine blocks one type of receptor for histamine (the H1 receptor) and thus prevents activation of cells by histamine. Unlike most other antihistamines, Fexofenadine does not enter the brain from the blood and, therefore, does not cause drowsiness. Fexofenadine lacks the cardiotoxic potential of terfenadine, since it does not block the potassium channel involved in repolarization of cardiac cells. Fexofenadine is sold under the trade name Allegra among others. ALLEGRA is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 2 years of age and older.

CNS Activity

Originator

Approval Year

1996
224
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
 246.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
ALLEGRA

Approved Use

ALLEGRA is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 2 years of age and older.

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
523.28 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27151911
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FEXOFENADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3507.8 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27151911
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FEXOFENADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
9.26 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27151911
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FEXOFENADINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
690 mg 2 times / day multiple, oral
Highest studied dose
Dose: 690 mg, 2 times / day
Route: oral
Route: multiple
Dose: 690 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
Other AEs: Headache, Tiredness...
Other AEs:
Headache (3 patients)
Tiredness (3 patients)
Dizziness (3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
800 mg single, oral
Highest studied dose
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
healthy, 26.9 years (range: 18-51) years
Health Status: healthy
Age Group: 26.9 years (range: 18-51) years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
Other AEs: Headache, Tiredness...
Other AEs:
Headache (3 patients)
Tiredness (3 patients)
Dizziness (3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
60 mg 2 times / day multiple, oral
Highest studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15209959
unhealthy, 6-11 years
Health Status: unhealthy
Age Group: 6-11 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15209959
Sources:
https://pubmed.ncbi.nlm.nih.gov/15209959
180 mg 1 times / day multiple, oral
Dose: 180 mg, 1 times / day
Route: oral
Route: multiple
Dose: 180 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22346270
unhealthy, 69 years
Health Status: unhealthy
Age Group: 69 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/22346270
Disc. AE: Papular urticarial eruption...
AEs leading to
discontinuation/dose reduction:
Papular urticarial eruption (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/22346270
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021909s000_MedR.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021909s000_MedR.pdf
Disc. AE: Headache...
AEs leading to
discontinuation/dose reduction:
Headache (2 patients)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021909s000_MedR.pdf
AEs

AEs

AESignificanceDosePopulation
Dizziness 3 patients
690 mg 2 times / day multiple, oral
Highest studied dose
Dose: 690 mg, 2 times / day
Route: oral
Route: multiple
Dose: 690 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
Headache 3 patients
690 mg 2 times / day multiple, oral
Highest studied dose
Dose: 690 mg, 2 times / day
Route: oral
Route: multiple
Dose: 690 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
Tiredness 3 patients
690 mg 2 times / day multiple, oral
Highest studied dose
Dose: 690 mg, 2 times / day
Route: oral
Route: multiple
Dose: 690 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
healthy, 18-55 years
Health Status: healthy
Age Group: 18-55 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
Dizziness 3 patients
800 mg single, oral
Highest studied dose
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
healthy, 26.9 years (range: 18-51) years
Health Status: healthy
Age Group: 26.9 years (range: 18-51) years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
Headache 3 patients
800 mg single, oral
Highest studied dose
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
healthy, 26.9 years (range: 18-51) years
Health Status: healthy
Age Group: 26.9 years (range: 18-51) years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
Tiredness 3 patients
800 mg single, oral
Highest studied dose
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
healthy, 26.9 years (range: 18-51) years
Health Status: healthy
Age Group: 26.9 years (range: 18-51) years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/9871426
Papular urticarial eruption 1 patient
Disc. AE
180 mg 1 times / day multiple, oral
Dose: 180 mg, 1 times / day
Route: oral
Route: multiple
Dose: 180 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22346270
unhealthy, 69 years
Health Status: unhealthy
Age Group: 69 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/22346270
Headache 2 patients
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021909s000_MedR.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021909s000_MedR.pdf
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:5050
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5050
ChemicalBook
CB5473513
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5473513
eMolecules
901886
https://www.emolecules.com/cgi-bin/more?vid=901886
MolPort
MolPort-002-508-207
https://www.molport.com/shop/molecule-link/MolPort-002-508-207
PubMed

PubMed

TitleDatePubMed
The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers.
2003-04
Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis.
2003-04
Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis.
2003-04
Spectrophotometric determination of binary mixtures of pseudoephedrine with some histamine H1-receptor antagonists using derivative ratio spectrum method.
2003-03-26
Solar urticaria induced by infrared radiation.
2003-03
Decongestant effects of antihistamines: a class effect?
2003-03
The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel.
2003-02
The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique.
2003-02
Failure of cetirizine and fexofenadine to prevent motion sickness.
2003-02
Effect of fexofenadine hydrochloride on cedar pollinosis.
2003-02
[Effect of fexofenadine--selective antagonist of histamine receptor (H1) on histamine-induced bronchoconstriction].
2003-01
Internal standard signal suppression by co-eluting analyte in isotope dilution LC-ESI-MS.
2003-01
Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
2003-01
Why aren't lower, effective, OTC doses available earlier by prescription?
2003-01
Chronic urticaria: a role for newer immunomodulatory drugs?
2003
Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain.
2002-12-20
Comparative pharmacology of H1 antihistamines: clinical relevance.
2002-12-16
Treatment of allergic rhinitis.
2002-12-16
Role of histamine in the pathophysiology of asthma: immunomodulatory and anti-inflammatory activities of H1-receptor antagonists.
2002-12-16
Sea transport of animal and vegetable oils and its environmental consequences.
2002-12
Effect of fexofenadine, a mast cell blocker, in infertile men with significantly increased testicular mast cells.
2002-12
Effects of fexofenadine on the early response to nasal allergen challenge.
2002-12
Facial swelling and eosinophilia in a 44-year-old woman.
2002-12
Inhibitory effects of oral prednisolone and fexofenadine on skin responses by prick tests with histamine and compound 48/80.
2002-12
Clinical pharmacology of H1-antihistamines in the skin.
2002-11
Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir.
2002-11
The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia.
2002-11
Determination of some histamine H1-receptor antagonists in dosage forms.
2002-10-15
The use of handheld computers in clinical trials.
2002-10
Review of fexofenadine in the treatment of chronic idiopathic urticaria.
2002-10
Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis.
2002-10
24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139].
2002-08-05
Simultaneous determination of fexofenadine and its related compounds by HPLC.
2002-07-20
Chronic urticaria and angioedema.
2002-07-18
In vivo anti-inflammatory effects of fexofenadine in chronic idiopathic urticaria.
2002-07
Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.
2002-07
Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit.
2002-07
Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness.
2002-07
Role of lung inflammatory mediators as a cause of exercise-induced arterial hypoxemia in young athletes.
2002-07
Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block.
2002-06-18
The Rx-to-OTC switch of Claritin, Allegra, and Zyrtec: an unprecedented FDA response to petitioners and the protection of public health.
2002-06
Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates.
2002-06
Effect of St John's wort on the pharmacokinetics of fexofenadine.
2002-06
Are herbal products dietary supplements or drugs? An important question for public safety.
2002-06
[Hay fever and asthma. Many of your patients have both].
2002-04-25
The use of antihistamines in safety-critical jobs: a meeting report.
2002
Urticaria to cetirizine.
2002
Liquid chromatography/tandem mass spectrometric bioanalysis using normal-phase columns with aqueous/organic mobile phases - a novel approach of eliminating evaporation and reconstitution steps in 96-well SPE.
2002
H1-antihistamines in children.
2002
Potential cardiac toxicity of H1-antihistamines.
2002
Patents

Patents

05925761
2
06479663
4
06566526
27
07671071
2
07700779
2
JP2003026658A
2
JP2005350459A
2
JP2005539044A
11
JP4722295B2
105
JP5308824B2
2

Sample Use Guides

In Vivo Use Guide
Seasonal Allergic Rhinitis and Chronic Idiopathic Urticaria Adults and Children 12 Years and Older: The recommended dose of ALLEGRA (Fexofenadine) tablets is 60 mg twice daily or 180 mg once daily with water. A dose of 60 mg once daily is recommended as the starting dose in patients with decreased renal function
Route of Administration: Oral
In Vitro Use Guide
The addition of fexofenadine at a dose of 10E-4 M elicited a significant relaxation response in isolated rat tracheas.
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:29:38 GMT 2025
Edited
by admin
on Wed Apr 02 07:29:38 GMT 2025
Record UNII
E6582LOH6V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FEXOFENADINE
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
TELFAST
Preferred Name English
FEXOFENADINE [USP-RS]
Common Name English
Fexofenadine [WHO-DD]
Common Name English
FEXOFENADINE [VANDF]
Common Name English
fexofenadine [INN]
Common Name English
(±)-P-(1-HYDROXY-4-(4-(HYDROXYDIPHENYLMETHYL)PIPERIDINO)BUTYL)-.ALPHA.-METHYLHYDRATROPIC ACID
Common Name English
FEXOFENADINE [MI]
Common Name English
4-(1-HYDROXY-4-(4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINYL)BUTYL)-ALPHA,ALPHA-DIMETHYLBENZENEACETIC ACID
Systematic Name English
BENZENEACETIC ACID, 4-(1-HYDROXY-4-(4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINYL)BUTYL)-.ALPHA.,.ALPHA.-DIMETHYL-, (±)-
Common Name English
FEXOFENADINE [HSDB]
Common Name English
Classification Tree Code System Code
NDF-RT N0000000190
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
WHO-ATC R06AX26
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
NDF-RT N0000175587
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
WHO-VATC QR06AX26
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
LIVERTOX NBK548571
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
NCI_THESAURUS C29578
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
Code System Code Type Description
DRUG CENTRAL
1170
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
CAS
83799-24-0
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
LACTMED
Fexofenadine
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
MESH
C093230
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
ChEMBL
CHEMBL914
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
HSDB
7486
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
WIKIPEDIA
FEXOFENADINE
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
IUPHAR
4819
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
RXCUI
87636
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY RxNorm
PUBCHEM
3348
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
FDA UNII
E6582LOH6V
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
MERCK INDEX
m5367
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY Merck Index
RS_ITEM_NUM
1270363
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
EVMPD
SUB13883MIG
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
NCI_THESAURUS
C61764
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
EPA CompTox
DTXSID00861411
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
SMS_ID
100000078495
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
CHEBI
5050
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
DRUG BANK
DB00950
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
INN
7469
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
DAILYMED
E6582LOH6V
Created by admin on Wed Apr 02 07:29:38 GMT 2025 , Edited by admin on Wed Apr 02 07:29:38 GMT 2025
PRIMARY
Related Record Type Details
Structure of FEXOFENADINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
OATP1B1
TRANSPORTER -> INHIBITOR
OATP1B1
TRANSPORTER -> SUBSTRATE
OATP-8
TRANSPORTER -> INHIBITOR
Structure of FEXOFENADINE
EXCRETED UNCHANGED
FECAL
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
Structure of FEXOFENADINE
EXCRETED UNCHANGED
URINE
OATP-B
TRANSPORTER -> SUBSTRATE
SOLUTE CARRIER FAMILY 21 MEMBER 3
TRANSPORTER -> SUBSTRATE
HISTAMINE H1 RECEPTOR
TARGET -> INHIBITOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
Related Record Type Details
Structure of TERFENADINE
PARENT -> METABOLITE ACTIVE
MAJOR
Related Record Type Details
Structure of FEXOFENADINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
PROTEIN BINDING PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Route of Elimination PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Route of Elimination PHARMACOKINETIC
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966